<DOC>
	<DOCNO>NCT01642667</DOCNO>
	<brief_summary>The aim study elucidate efficacy safety pharmacoinvasive therapy use prourokinase ( prouk ) , unique fibrin-specific agent , patient ST-segment elevation myocardial infarction ( STEMI )</brief_summary>
	<brief_title>Pharmacoinvasive Therapy With Prourokinase</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Saruplase</mesh_term>
	<criteria>age 75 year young , symptom onset 6 h less randomization , intention undertake primary PCI , STsegment elevation 2 mm two anterior lead 1 mm two inferior lead STsegment elevation , new leave bundlebranch block . expect arrival catheterization laboratory le 1 h 3 h randomization , anticipate problem vascular access , previous enrollment study , usual contraindication thrombolytic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>